Zacks Short Term Rating on Rockwell Medical, Inc. (NASDAQ:RMTI) - OTC Outlook PDF Print

As many as 5 brokerage firms have rated Rockwell Medical, Inc. (NASDAQ:RMTI) at 2.2. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of hold for the short term. 1 analysts have rated it as strong sell. The stock garnered a place in the hold list of 1 stock Analysts. 3 analysts rated the company as a strong buy.

Rockwell Medical, Inc. (NASDAQ:RMTI): The stock price is expected to reach $ 16.6 in the short term. The number of analysts agreeing with this consensus is 5. The higher estimate for the short term price target is at $26 while the lower estimate is at $4. The standard deviation of the price stands at $7.99. Many analysts have commented on the company rating. In a research note released to the investors, Bank of America reinstates its rating on Rockwell Medical, Inc. (NASDAQ:RMTI).The analysts at the brokerage house have a current rating of Neutral on the shares. The rating by the firm was issued on July 8, 2015. Rockwell Medical, Inc. (NASDAQ:RMTI) rose 0.86% or 0.12 points on Monday and made its way into the gainers of the day. After trading began at $14.15 the stock was seen hitting $14.53 as a peak level and $13.98 as the lowest level. The stock ended up at $14.09. The daily volume was measured at 533,528 shares. The 52-week high of the share price is $18.8999 and the 52-week low is $8.095. The company has a market cap of $708 million. Currently the company Insiders own 5.5% of Rockwell Medical, Inc. Company shares. In the past six months, there is a change of 0% in the total insider ownership. Institutional Investors own 34.4% of Company shares. During last 3 month period, 25.61% of total institutional ownership has changed in the company shares. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.


Share |
Copyright © 2018 Global Dialysis. All Rights Reserved.